admin – Page 3017 – Get News Story

Diffuse Large B-Cell Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 70+ Companies and 75+ Therapies | DelveInsight

DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Diffuse Large B-Cell Lymphoma pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Diffuse Large B-Cell Lymphoma Pipeline Report to explore emerging therapies, key Diffuse Large B-Cell Lymphoma Companies, and future Diffuse Large B-Cell Lymphoma treatment landscapes @ Diffuse Large B-Cell Lymphoma Pipeline Outlook Report

Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report

In June 2025, Genmab announced a study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed.
In June 2025, Mitsubishi Tanabe Pharma Corporation conducted a phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL.
DelveInsight’s Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment.
The leading Diffuse Large B-Cell Lymphoma Companies such as Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Promising Diffuse Large B-Cell Lymphoma Therapies such as Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.

Discover how the Diffuse Large B-Cell Lymphoma treatment paradigm is evolving. Access DelveInsight’s in-depth Diffuse Large B-Cell Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Diffuse Large B-Cell Lymphoma Clinical Trials and Studies

Diffuse Large B-Cell Lymphoma Emerging Drugs Profile

Brentuximab vedotin: Pfizer

Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It is indicated for the treatment of patients with Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. Adcetris is also indicated for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT), also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma, for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric treatment for CD30-positive Hodgkin lymphoma. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.

THOR-707: Sanofi

THOR-707 is a precisely PEGylated version of IL-2, where the PEG chain is attached to a novel amino acid inserted at a location on IL-2 that prevents it from engaging the alpha-receptor and binding to immune receptors that cause drug toxicities (IL-2R-alpha, CD25). The engineered IL-2 retains near-native binding to the beta-gamma receptors that selectively expand tumor-killing T effector cells and Natural Killer (NK) cells without the alpha-mediated immunosuppressive effects of regulatory T cells or eosinophil-mediated vascular leak syndrome. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.

Abexinostat: Xynomic Pharmaceuticals

Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B-cell lymphoma.

RNK05047: Ranok Therapeutics

RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok’s proprietary approach to targeted protein degradation, CHAMPTM. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. CHAMP-1 is a Phase I/II trial of RNK05047 currently underway in the US that will assess its safety, tolerability, and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamics readouts as secondary endpoints.

BMF-219: Biomea Fusion

BMF-219 is an oral investigational covalent menin inhibitor. Data suggests that optimized covalent inhibitors can provide deeper inhibition while being better tolerated than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, MM and CLL patients. BMF-219 blocks the interaction of menin and MLL (AML, ALL), and limits the activity and/or expression of NPM1, MYC, HOX, and MEIS1, all known drivers of oncogenic proliferation and survival. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.

ADI-001: Adicet Bio

ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the FDA for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.

The Diffuse Large B-Cell Lymphoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Diffuse Large B-Cell Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-Cell Lymphoma Treatment.
Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diffuse Large B-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diffuse Large B-Cell Lymphoma market.

Get a detailed analysis of the latest innovations in the Diffuse Large B-Cell Lymphoma pipeline. Explore DelveInsight’s expert-driven report today! @ Diffuse Large B-Cell Lymphoma Unmet Needs

Diffuse Large B-Cell Lymphoma Companies

Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.

Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Diffuse Large B-Cell Lymphoma Therapies and key Diffuse Large B-Cell Lymphoma Developments @ Diffuse Large B-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report

Coverage- Global
Diffuse Large B-Cell Lymphoma Companies- Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Diffuse Large B-Cell Lymphoma Therapies– Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.
Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Diffuse Large B-Cell Lymphoma drug development? Find out in DelveInsight’s exclusive Diffuse Large B-Cell Lymphoma Pipeline Report—access it now! @ Diffuse Large B-Cell Lymphoma Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
Diffuse Large B-Cell Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Diffuse Large B-Cell Lymphoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Brentuximab vedotin: Pfizer
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
THOR-707: Sanofi
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ADI-001: Adicet Bio
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Diffuse Large B-Cell Lymphoma Key Companies
Diffuse Large B-Cell Lymphoma Key Products
Diffuse Large B-Cell Lymphoma- Unmet Needs
Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers
Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion
Diffuse Large B-Cell Lymphoma Analyst Views
Diffuse Large B-Cell Lymphoma Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diffuse Large B-Cell Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 70+ Companies and 75+ Therapies | DelveInsight

Cystinosis Treatment Market Set for Robust Growth Through 2034, Driven by Recent Developments in Clinical Pipeline | DelveInsight

The cystinosis treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including Horizon Pharma, Chiesi Farmaceutici, Recordati S.p.A, Nacuity Pharma, AVROBIO, Eloxx Pharmaceuticals, Mylan Pharmaceuticals, Leadiant Biosciences, Novartis, and others.

DelveInsight’s “Cystinosis Market Insight, Epidemiology And Market Forecast – 2034” report delivers an in-depth understanding of the cystinosis treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and cystinosis market forecasts through 2034, offering vital insights for stakeholders in the cystinosis therapeutic area.

According to DelveInsight’s analysis, the cystinosis market size is anticipated to grow with a significant CAGR during the forecast period (2024-2034), driven by enhanced understanding of disease mechanisms, biomarker development, and personalized medicine approaches.

Download the Cystinosis Market report to understand which factors are driving the Cystinosis therapeutic market @ Cystinosis Market Trends.

According to DelveInsight’s estimates, the total number of prevalent cystinosis cases in the United States was estimated to be around 1,300 in 2023. Furthermore, the total prevalent population of cystinosis in the EU4 countries and the UK was estimated at approximately 1,600 cases.

Additionally, the United States reported the highest number of diagnosed prevalent cases of cystinosis, with around 680 cases. Within the EU4 and the UK, the UK had the most cases, followed by Germany, France, and Spain, while Italy had the fewest.

The DelveInsight report further categorizes the cystinosis patient population into several main groups for analysis. In the 7MM, there were an estimated 1,250 cases of infantile nephropathic cystinosis, 65 cases of juvenile nephropathic cystinosis, and 45 cases of adult-onset (ocular or non-nephropathic) cystinosis. Most cystinosis cases are contributed by nephropathic cystinosis, with the least contributed by the ocular type. This classification is essential for understanding the distribution, progression, and treatment responses of different cystinosis types and is crucial for accurate epidemiological assessment.

Discover evolving trends in the Cystinosis patient pool forecasts @ Cystinosis Epidemiology Analysis.

While there is no definitive cure for cystinosis, several treatment options are aimed at cystinosis management and potentially slowing disease progression. The standard treatment for cystinosis involves cysteamine bitartrate therapy, which reduces cystine levels through immediate or delayed-release formulations. PROCYSBI (cysteamine bitartrate delayed-release capsules) and CYSTADROPS (cysteamine ophthalmic solution) are approved treatments that help prevent cystine buildup.

A milestone in cystinosis treatment occurred with the development of PROCYSBI by Horizon Pharma, marking a significant advancement in nephropathic cystinosis therapy. Chiesi Farmaceutici completed the acquisition of European marketing rights to PROCYSBI in 2017, enhancing their rare disease portfolio. CYSTADROPS, developed for corneal cystine crystal accumulation, requires only 4 daily treatments compared to the frequent hourly dosing previously required, significantly reducing treatment burden for patients.

The cystinosis treatment market is highly competitive, with major players including Horizon Pharma, Chiesi Farmaceutici S.p.A., Recordati Rare Diseases, Nacuity Pharmaceuticals, AVROBIO Inc., Eloxx Pharmaceuticals, Mylan Pharmaceuticals, Leadiant Biosciences, Novartis AG, and others, advancing a variety of therapies through robust R&D and strategic collaborations.

Key players are focused on developing innovative drug therapies, particularly cysteamine-based treatments and gene therapies, which are showing promise in alleviating symptoms and enhancing quality of life for patients.

According to the DelveInsight report, the cystinosis therapies pipeline includes several novel treatments in late-stage development. AVROBIO’s AVR-RD-04, an investigational gene therapy, has shown encouraging results in Phase I/II clinical trials. This gene therapy genetically modifies patients’ hematopoietic stem cells to express functional cystinosin, potentially addressing the root cause of the disease. AVR-RD-04 has received Rare Pediatric Disease Designation and Fast Track Designation from the FDA, as well as Orphan Drug Designation from both the FDA and the EMA, fast-tracking the clinical development.

Recent developments highlight the dynamic nature of the cystinosis treatment landscape. Following Novartis’s acquisition of AVROBIO’s cystinosis gene therapy program in May 2023 for $87.5 million, the company launched the CYStem Phase I/II clinical trial in April 2025. This open-label, multi-center study is evaluating DFT383 (formerly AVR-RD-04) in children aged 2-5 years with nephropathic cystinosis, representing the first gene therapy clinical trial specifically designed for pediatric cystinosis patients and builds upon the positive safety and efficacy data from the original Phase I/II trial in adults.

Discover recent advancements in the Cystinosis treatment landscape @ Cystinosis Recent Developments.

Looking ahead, the cystinosis market is expected to witness continued innovation driven by enhanced understanding of disease mechanisms, biomarker development, and personalized medicine approaches. The dynamics of the cystinosis market are set to evolve with heightened competition among pharmaceutical companies, which could lead to better accessibility, affordability, and innovation in treatment options. Advancements in gene therapy and precision medicine have the potential to redefine treatment approaches, offering hope for patients with this rare genetic disorder.

DelveInsight’s analysis underscores that despite therapeutic advances, substantial opportunities remain for developing more effective, convenient, and affordable treatment options that can achieve durable cystine depletion and improved quality of life for cystinosis patients worldwide. As research continues and awareness grows, the cystinosis market is poised for remarkable expansion and therapeutic innovation.

Table of Contents

1. Key Insights

2. Executive Summary of Cystinosis

3. Competitive Intelligence Analysis for Cystinosis

4. Cystinosis: Market Overview at a Glance

5. Cystinosis: Disease Background and Overview

6. Cystinosis Patient Journey

7. Cystinosis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Cystinosis Unmet Needs

10. Key Endpoints of Cystinosis Treatment

11. Cystinosis Marketed Products

12. Cystinosis Emerging Therapies

13. Cystinosis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Cystinosis

17. KOL Views

18. Cystinosis Market Drivers

19. Cystinosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports:

Cystinosis Pipeline Insight

Cystinosis Pipeline Insight provides comprehensive insights about the Cystinosis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Cystinosis companies, including AVROBIO, Birch Therapeutics, and Nacuity Pharmaceuticals, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cystinosis Treatment Market Set for Robust Growth Through 2034, Driven by Recent Developments in Clinical Pipeline | DelveInsight

NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies | DelveInsight

DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the NASH Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NASH Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the NASH Pipeline. Dive into DelveInsight’s comprehensive report today! @ NASH Pipeline Outlook

Key Takeaways from the NASH Pipeline Report

In May 2025, Novo Nordisk A/S announced a study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
In May 2025, Akero Therapeutics Inc. conducted a phase 2b study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH).
DelveInsight’s NASH Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for NASH treatment.
The leading NASH Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others.
Promising NASH Pipeline Therapies such as Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others.

Stay ahead with the most recent pipeline outlook for NASH. Get insights into clinical trials, emerging therapies, and leading companies with NASH@ NASH Treatment Drugs

NASH Emerging Drugs Profile

Lanifibranor: Inventiva Pharma

Lanifibranor, Inventiva’s lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While other PPAR agonists target only one or two PPAR isoforms for activation. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH. Currently, the drug is in Phase III stage of its clinical trial for the treatment of NASH.

MSDC-0602K: Cirius Therapeutics

MSDC-0602K, a second-generation oral insulin sensitizer, is designed to selectively modulate the mitochondrial pyruvate carrier (MPC) while minimizing direct PPAR-gamma activation. The MPC mediates at the cellular level the effects of over nutrition, a major cause of Nonalcoholic fatty liver disease NAFLD/NASH and Type 2 diabetes. In preclinical studies, modulation of the MPC has been shown to improve insulin sensitivity, lipid metabolism, and inflammation. Currently the drug is in Phase III stage of Clinical trial for the treatment of NASH.

TERN-501: Terns Pharmaceuticals

TERN-501 is a THR-β agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development. Agonism of THR-β increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR-β stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR-β than for THR-α activation in a cell free assay, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of NASH.

HTD 1801: HighTide Biopharma

The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity (ionic salt of two active moieties). It is a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM). Currently, it is in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH).

The NASH Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of NASH with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NASH Treatment.
NASH Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
NASH Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NASH market

Explore groundbreaking therapies and clinical trials in the NASH Pipeline. Access DelveInsight’s detailed report now! @ New NASH Drugs

NASH Companies

Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others.

Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

NASH Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of NASH Treatment. Learn about new drugs, NASH Pipeline developments, and key companies with DelveInsight’s expert analysis @ NASH Market Drivers and Barriers

Scope of the NASH Pipeline Report

Coverage- Global
NASH Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others.
NASH Pipeline Therapies- Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others.
NASH Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
NASH Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on NASH Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ NASH Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Nonalcoholic Steatohepatitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Nonalcoholic Steatohepatitis– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Lanifibranor: Inventiva Pharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
TERN-501: Terns Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
LY3849891: Eli Lilly and Company
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name : Company name
Drug profiles in the detailed report…..
Inactive Products
Nonalcoholic Steatohepatitis Key Companies
Nonalcoholic Steatohepatitis Key Products
Nonalcoholic Steatohepatitis- Unmet Needs
Nonalcoholic Steatohepatitis- Market Drivers and Barriers
Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
Nonalcoholic Steatohepatitis Analyst Views
Nonalcoholic Steatohepatitis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies | DelveInsight

Satellite NTN Market worth $2.79 Billion by 2030, at a CAGR of 38.0%

“Satellite NTN Market”

The Satellite NTN Market is projected to grow from USD 0.56 billion in 2025 to USD 2.79 billion by 2030 at a CAGR of 38.0%.

The report “Satellite NTN Market by Technology (NR NTN, IoT NTN), Hardware (RF Front End, Antenna, Onboard Processors), Application (eMBB, mMTC, uRLLC), Frequency (L, S, C, Ku and Ka, HF/VHF/UHF-band), Orbit, End Use and Region – Global Forecast to 2030” The satellite NTN market is projected to grow from USD 0.56 billion in 2025 to USD 2.79 billion by 2030 at a CAGR of 38.0%. The satellite NTN (non-terrestrial network) market is growing rapidly due to its integration with 5G technology. This means people can get strong, more reliable connections in remote areas or even when traveling. The older satellites were away from the Earth and often delayed. However, the new Leo (Low Earth Orbit) satellites are very close and can handle video calls and online games.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=185084281

Browse 177 market data Tables and 71 Figures spread through 235 Pages and in-depth TOC on “Satellite NTN Market”

View detailed Table of Content here – https://www.marketsandmarkets.com/Market-Reports/satellite-ntn-market-185084281.html

Improvements in satellite equipment, like lighter antennas that can point more accurately, make satellite networks more flexible and reliable. Additionally, reusable rockets have made a large number of satellite launches reasonable. These satellite networks are becoming critical in areas like driverless cars, smart farming, and secure military communication. All these factors point toward the progress the satellite NTN market has made in the past few years. As governments create new rules to manage satellite signals, the satellite NTN industry is expected to expand beyond traditional uses.

By application, the mMTc segment is projected to be the fastest-growing segment in the satellite NTN market during the forecast period

The mMTC (Massive Machine-Type Communications) segment is projected to be the fastest-growing segment in the Satellite NTN Industry during the forecast period. This growth can be attributed to the rampant use of IoT devices and the increasing demand for ubiquitous, low-power, wide-area connectivity. Additionally, the need for environmental monitoring and precision agriculture, smart logistics, and infrastructure management demanding continuous data transmission in remote areas where terrestrial networks can’t reach is also driving the mMTC applications of satellite NTNs.

Satellite NTN enables global reach with minimal latency and high scalability, ideally enabling millions of connected devices and sensors. LEO constellations and advancements in small, low-power satellite terminals accelerate the adoption of mMTC systems even more. The maritime, oil & gas, and transportation sectors rely on robust, real-time data from dispersed assets, making satellite NTN the foundation for robust global IoT ecosystems.

By frequency, the L-band segment is projected to lead the satellite NTN market during the projected period.

The L-band segment is projected to lead the satellite NTN market during the projected period due to the ideal combination of coverage, penetration, and reliability in satellites operating on L-band frequencies, which offer improved signal propagation through barriers like buildings and vegetation compared to higher bands and are suited for mobile and remote applications like maritime, aviation, and emergency communications. The L-band system also requires a simple and small antenna design, which reduces terminal expenses and enables universal distribution in IoT and MMTC applications. The signal frequently connects to the tape’s immune environment for declining weather conditions. Regulatory support and investment in the existing infrastructure of L-band frequencies also translate into rapid distribution and inter-revolution.

North America is projected to lead the satellite NTN market during the forecast period

During the forecast period, North America is projected to dominate the satellite NTN market, with its robust technology ecosystem, government support, and large industry players. The US is particularly driving growth, with massive LEO satellite launches by SpaceX and Amazon’s Project Kuiper, supported by friendly FCC regulations that facilitate spectrum allocation and licensing. Additionally, substantial investments from the private and public sectors fuel innovation in satellite technology, basic infrastructure, and 5G integration. Also, North America’s advanced telecommunication networks and an early 5G adoption enable seamless terrestrial satellite connection, which extends cases of NTN use in commercial, defense, and emergency areas. This combination of regulator bank, state-of-the-art innovation, and market demand ranks North America as a global satellite NTN market leader.

Airbus (Netherlands), Thales Alenia Space (France), Kongsberg (Norway), Analog Devices, Inc. (US), and NEC Corporation (Japan) are the major key players in the Satellite NTN Companies. These companies have strong distribution networks across regions like North America, Europe, Asia Pacific, and the Rest of the World.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Delray Beach
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/satellite-ntn-market-185084281.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Satellite NTN Market worth $2.79 Billion by 2030, at a CAGR of 38.0%

Pharmacy Automation Market worth US$10.00 billion by 2030 with 7.1% CAGR | MarketsandMarkets™

“The United Nations Population Fund (UNFPA) predicts people aged 65 and older will grow from our present 10.3% worldwide population in 2024 to 20.7% by 2074, leading to a surge in the number of elderly patients requiring long-term medication management. Based on a Harvard University housing study 2023, almost 70% of elderly people (over age 65) are likely to need long-term assistance in their lifespan”

Browse 387 market data Tables and 50 Figures spread through 388 Pages and in-depth TOC on “Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counter, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient, Retail, ASC), Facility (Large, Mid) – Global Forecast to 2030

The global Pharmacy Automation Market, valued at US$6.23 billion in 2023, is forecasted to grow at a robust CAGR of 7.1%, reaching US$6.65 billion in 2024 and an impressive US$10.00 billion by 2030. The growth of the market is mainly fueled by the increasing incidence of chronic diseases, enhancing the need for effective and precise management of drugs. Moreover, the requirement of efficient pharmacy operations to boost the efficiency of the workflow and cut down medication mistakes is accelerating the usage of automation. Furthermore, government initiatives and policies promoting digital health and automation are propelling market growth.

Furthermore, major industry players are increasingly focusing on AI-driven solutions, cloud-based pharmacy management systems, and strategic partnerships to enhance operational efficiency. The expansion of e-pharmacies, along with the growing integration of IoT in healthcare, is expected to create new growth opportunities. As technological advancements continue to transform the pharmacy sector, automation is becoming an essential solution for improving medication safety, reducing costs, and optimizing overall pharmaceutical operations.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71522890

Browse in-depth TOC on “Pharmacy Automation Market“

200 – Tables

50 – Figures

300 – Pages

By Based on product type, the pharmacy automation market has been segmented into automated medication dispensing and storage systems, automated packaging and labeling systems, automated tabletop counters, automated medication compounding systems, pharmacy management software (PMS/PIMS/PIS), and other pharmacy automation systems (pharmacy kiosks, pneumatic tubes, tablet splitters, and others). In 2023, the automated medication dispensing and storage systems segment is estimated to hold the largest share of the market for pharmacy automation. Some of the key growth factors for the segment are increasing need for reducing medication errors. Medication dispensing errors, such as incorrect dosage, wrong medications, and dispensing delays, contribute to adverse drug events (ADEs), impacting patient health outcomes. For instance, according to the World Health Organization (WHO) 2022, medication errors are estimated to cost approximately USD 42 billion annually. Further, in hospital settings, medication error rates range from 0.3% to 9.1% during prescribing and 1.6% to 2.1% at the dispensing stage. Automation minimizes human errors by ensuring precise dispensing and secure storage. Technologies such as robotic dispensers help prevent contamination and ensure correct medication dispensing.

By End user, the retail pharmacies segment is expected to grow at the fastest CAGR over the forecast period. This rapid expansion is fueled by the rising demand for streamlined pharmacy operations, growing prescription volumes, and the need for faster, more accurate medication dispensing. The increasing shift toward digital health solutions, coupled with advancements in robotic dispensing, AI-driven inventory management, and cloud-based pharmacy systems, is transforming how retail pharmacies operate. Additionally, the push for improved customer convenience, including same-day prescription deliveries and automated refill systems, is accelerating the adoption of pharmacy automation technologies. Major retailers such as Walmart and Amazon are intensifying competition in the US prescription medication market by introducing same-day delivery services. For instance, in January 2025, Walmart announced the nationwide expansion of its same-day pharmacy delivery service in 49 states by the end of January 2025. This move intensifies competition with Amazon’s expanding prescription services and traditional retail pharmacies such as CVS and Walgreens, which are struggling with store closures. The service aims to provide faster, more convenient prescription access for customers, particularly busy families, seniors, and chronic disease patients.

By geography, the pharmacy automation market is segmented into five major regions: North America, Asia Pacific, Europe, Middle East & Africa, and Latin America. In 2023, North America accounted for the highest share in pharmacy automation market driven by its well-established healthcare infrastructure, high adoption of advanced technologies, and stringent regulatory requirements for medication safety. The region’s dominance is fueled by the increasing demand for automated medication dispensing, packaging, and inventory management solutions in both hospital and retail pharmacy settings. Regulatory bodies such as the FDA, DEA, and HIPAA have set strict guidelines for medication management, pushing pharmacies and healthcare institutions to integrate automation to ensure compliance and reduce medication errors. Additionally, the presence of leading market players, including Omnicell, BD, Swisslog Healthcare, and Baxter International Inc, accelerated innovation and widespread adoption of automation technologies. The rise of retail pharmacy automation, with major chains such as Walmart, CVS, Walgreens, and Amazon Pharmacy investing in AI-powered prescription fulfillment and same-day delivery services, further strengthened North America’s leadership in the market.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=71522890

The pharmacy automation market is consolidated at the top with a large number of leading market players based in developed countries. The key players operating in this market are Becton, Dickinson and Company (US), Omnicell, Inc. (US), KUKA AG (Swisslog Healthcare) (Germany), Baxter International Inc. (US), Capsa Healthcare (US), Oracle (US), Yuyama Co., Ltd. (Japan), ARxIUM Inc. (US), Mckesson Corporation (US), RxSafe, LLC (US), ScriptPro LLC (US), Pearson Medical Technologies, LLC (US), Deenova S.R.L (Germany), Medical Packaging Inc., LLC (US), Tension Corporation (US), Noritsu Pharmacy Automation (US), Euclid Medical Products (US), TouchPoint Medical Solutions (US), Innovation Associates (US), and JFCRX (US). Because of the high level of competition in the market, major market players are becoming more inclined to grow their presence in the high-growth markets by employing both organic and inorganic growth initiatives like product launches, and acquisitions.

Becton, Dickinson and Company (BD) (US):

BD is a worldwide manufacturer of high-quality pharmacy automation solutions that reinforce its market position via organic growth strategies like investments in research & development activities. BD spent USD 1.33 billion and USD 1.09 billion in R&D in 2021 and 2020, respectively. Further, the strong geographical presence, extensive distribution network, and brand image of the company has made itself a market leader in the worldwide arena.

Omnicell, Inc. (US):

Omnicell is among the most dominant companies in the pharmacy automation sector. The firm has a very wide line of pharmacy automation systems with high brand value that has enabled it to establish a competitive advantage in the pharmacy automation sector and a leading global position. The firm has a focus on inorganic expansion through acquiring firms. Omnicell bought MarkeTouch Media, LLC (US) to further its presence in the retail pharmacy market. It also bought ReCept Holdings, Inc. (US) to further its portfolio of advanced services.

KUKA AG (Swisslog Healthcare) (Germany):

KUKA AG (Swisslog Healthcare) (Germany): KUKA provides an extensive array of pharmacy automation solutions under its Swisslog Healthcare business segment. Swisslog Healthcare emphasizes growing its business by expanding product development and geographical presence. Swisslog Healthcare expanded its business through the development of the UniPick 2 outpatient drug dispensing automation solution in hospital pharmacies (outpatient solutions) in the fast-expanding Chinese market. New products established and improvements have given Swisslog a competitive edge over its peers in the market.

For more information, Inquire Now!

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/pharmacy-automation-systems-market-71522890.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pharmacy Automation Market worth US$10.00 billion by 2030 with 7.1% CAGR | MarketsandMarkets™

Sleep Apnea Oral Appliances Market worth US$0.8 billion by 2030 9.8% CAGR | MarketsandMarkets™

“The prominent players in the sleep apnea oral appliances market include dSomnoMed (Australia), Resmed (US), ProSomnus Sleep Technologies (US), DynaFlex (US), Vivos Therapeutics, Inc. (US)”

Browse 310 market data Tables and 45 Figures spread through 250 Pages and in-depth TOC on “Sleep Apnea Oral Appliances Market by Product (Mandibular Advancement Devices (MAD), Tongue-Retaining Devices (TRD)), Purchase Type (Physician-prescribed), Gender (Male, Female), Age Group, Distribution Channel (Online, Retail) – Global Forecast to 2030

The global Sleep Apnea Oral Appliances Market, valued at US$0.4 billion in 2024, is forecasted to grow at a robust CAGR of 9.8%, reaching US$0.5 billion in 2025 and an impressive US$0.8 billion by 2030. The growth of the sleep apnea oral appliances market is primarily driven by an increasing number of patients with undiagnosed sleep apnea and a better understanding of the consequences of untreated sleep apnea. Additionally, rising awareness of sleep apnea products introduced by major players in the market is expected to impact market growth significantly.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105423877

Browse in-depth TOC on “Sleep Apnea Oral Appliances Market“

310 – Tables

45 – Figures

250 – Pages

By Based on product, the sleep apnea oral appliances market is divided into mandibular advancement devices, tongue-retaining devices, and daytime-nighttime appliances. The mandibular advancement devices segment dominated the market during the forecast period. These devices have gained widespread acceptance due to their ease of use and clinical efficacy. They are designed to reposition the lower jaw, which helps keep the upper airway clear for breathing and reduces episodes of obstructive sleep apnea. Mandibular Advancement Devices (MADs) are specifically used for patients with mild to moderate obstructive sleep apnea. As awareness of sleep apnea and its management increases, there is a growing demand for non-invasive and comfortable devices that patients can use for extended periods.

By end user, the sleep apnea oral appliances market is segmented into home care settings/individuals, hospitals, and dental clinics. In 2024, the home care settings/individuals segment accounted for the largest share of the market. The primary reason for the popularity of oral appliances is their worldwide availability. These appliances are user-friendly and comfortable, requiring no special care after being fitted by a physician; thus, making them ideal for home care settings. Additionally, growing awareness about sleep apnea and its management has led to increased acceptance of these appliances among the public.

By geography, the sleep apnea oral appliances market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America accounted for the largest market share. The large share of this region can be attributed to increasing obesity and lifestyle diseases in North America, advancements in the healthcare sector, and the development of innovative products manufactured by the companies in the region.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=105423877

The prominent players in the sleep apnea oral appliances market include dSomnoMed (Australia), Resmed (US), ProSomnus Sleep Technologies (US), DynaFlex (US), Vivos Therapeutics, Inc. (US), OpenAirway (Canada), Panthera Dental (Canada), Airway Management (US), Apnea Sciences (US), OravanOSA (US), Myerson LLC (US), and Braebon Medical Corporation (Canada), among others.

SomnoMed (Australia)

In 2024, SomnoMed ranked among the leading sleep apnea oral appliances market companies. The company has a strong distribution network in Europe and North America and is actively working on expanding its geographic presence along with its product portfolio. In recent years, SomnoMed has expanded its product portfolio to include innovative solutions. The firm’s product launches are manufactured using ISO 13485 quality standards and FDA clearance.

ResMed (US)

ResMed focuses on delivering innovative product launches and substantial investments in R&D capabilities. The company consistently provides advanced technology-driven solutions to manage sleep apnea. ResMed is focused on expanding and increasing its geographical presence. For instance, the firm expanded its presence by inauguring ResMed’s manufacturing center in Singapore. This development is expected to expand the company’s presence in emerging markets of the Asia Pacific region, thus solidifying its position in the sleep apnea oral appliances market.

ProSomnus Sleep Technologies (US)

In 2024, ProSomnus held a significant share of the sleep apnea oral appliances market due to its commitment to innovation, design, manufacturing, and commercialization. The company provides non-invasive, comfortable, and convenient devices for managing sleep apnea. ProSomnus’s highly automated and scalable manufacturing process sets it apart in the market, which ensures exceptional precision. Additionally, the company’s continuous investment in research and strategic partnerships strengthens its position in the industry. ProSomnus focuses on advanced digital workflows and custom-fit solutions for patients.

For more information, Inquire Now!

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/sleep-apnea-oral-appliances-market-105423877.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sleep Apnea Oral Appliances Market worth US$0.8 billion by 2030 9.8% CAGR | MarketsandMarkets™

Mark Farias Releases New Album Gasoline Milkshake

Mark Farias drops his explosive new album, Gasoline Milkshake—a brilliant fusion of classic and modern rock that’s sure to electrify rock fans everywhere.

This trailblazing, hell-raising, jaw-dropping release features five infectious anthems that deliver everything you crave in a song—and more. The lineup: “Up Against The Wall,” “Paradise Lost,” “Fallin,” “Broken Dream,” and “Moonlight Generation.” Each track tells a vivid story, bursting with passion and intensity that resonates in every chord and lyric.

Gasoline Milkshake is more than just an album—it’s a statement: Rock is here to stay. Every song pulses with energy, power, and intricate melodies, weaving a dreamlike landscape of sound and emotion that pulls listeners in from the first note.

Much of the album’s magic comes from the supernatural talent of producer, engineer, and musical visionary Nick “Fury” Fontaine. His innovative approach to production played a vital role in bringing these sonic gems to life.

About the Artist

Mark Farias is a gifted artist in every sense of the word—known for his ability to craft unforgettable melodies infused with his signature brand of rock ’n’ roll swagger.

His latest release, Gasoline Milkshake, is a hypnotic groove that sinks its teeth in and doesn’t let go. The album is available now on all major digital platforms worldwide.

Listen on Spotify.

Media Contact
Company Name: Mark Farias Music
Contact Person: Mark Farias
Email: Send Email
Country: United States
Website: https://musictalkers.com/latest-news/92-featured/9776-%E2%80%9Cgasoline-milkshake%E2%80%9D-mark-farias-ignites-rock%E2%80%99s-next-great-revival

Cookie Single by Intelligent Diva & AI Reimaginated: Chincia Kenner’s Historic First Independent AI Fashion Show on IMDb

In a groundbreaking fusion of technology, fashion, and music, AI Reimaginated: The AI Fashion Show Series has become the first independent AI-driven fashion show to be officially recognized on IMDb. This milestone marks a significant achievement for independent creators and the evolving landscape of AI in the fashion industry.

A Vision Realized

The series, now in its inaugural season, is the brainchild of Chincia Kenner, known artistically as Intelligent Diva. Serving as both the AI fashion designer and musical artist, Kenner has seamlessly integrated her technological expertise with her creative vision. The series features music exclusively from Intelligent Diva Music and Diva Underground Records, highlighting the synergy between AI-generated fashion and original soundtracks.

Breaking Barriers

AI Reimaginated stands as a testament to the possibilities that arise when technology and creativity intersect. By leveraging AI tools, Kenner has overcome traditional barriers in fashion show production, such as high costs and resource limitations. This approach not only democratizes fashion but also showcases how small businesses can innovate without extensive budgets.

Introducing Chelsea: The AI Host

Adding a unique dimension to the series is Chelsea, an AI-generated host created by Kenner. Chelsea guides viewers through each episode, embodying the potential of AI in enhancing viewer engagement and experience. This integration of an AI host in a fashion series is a pioneering move, setting a new standard for future productions.

Expanding the Fashion Frontier

Kenner’s innovation doesn’t stop at virtual runways. She has launched an NFT fashion show that features both digital fashion and physical NFT products from the IDM Merch Boutique. This initiative bridges the gap between digital and physical fashion, offering audiences a unique and immersive experience.

The I CANNOT Shoe Collection

Building upon her I CANNOT Fashion Collection, Kenner has introduced the I CANNOT Shoe Collection in partnership with Alive Shoes. This expansion reflects her commitment to empowering individuals through fashion that makes a statement.

Catch Intelligent Diva on Indie On The Rise

Fans can catch Intelligent Diva this month on Indie On The Rise, where she will discuss her journey and the innovative projects she’s spearheading. Stay tuned for more details on this appearance.

Experience the Fashion Shows

Cookie Contour Fashion Show: Watch on YouTube
NFT AI Fashion Show: Watch on YouTube
AI Reimaginated Series: Available on Vimeo and Roku

Stream the New Single “Cookie”

Intelligent Diva’s latest single, “Cookie,” is now available for streaming on Spotify. The track complements the fashion series, embodying the fusion of music and digital fashion.

About Intelligent Diva

Chincia Kenner, professionally known as Intelligent Diva, is a multifaceted artist and technologist. With certifications in various technological fields, she brings a unique perspective to the creative industry, merging technical skills with artistic expression.

Media Contact
Company Name: Intelligent Diva Music
Contact Person: Chincia Kenner
Email: Send Email
Country: United States
Website: https://intelligentdivamusic.com/

Traditional Wound Care Market worth $9.12 billion by 2030 | MarketsandMarkets™

“Prominent players in the Traditional wound care market include, Solventum (US), Cardinal Health (US), Smith+Nephew (UK), Nitto Denko Corporation (Japan), MCKESSON CORPORATION (US), Beiersdorf (Germany)”

Browse 401 market data Tables and 50 Figures spread through 372 Pages and in-depth TOC on “Traditional Wound Care Market by Product (Fixation, Bandages, Gauze, First Aid Plasters, Dressings), Application (Chronic, Acute Wounds), End User (Hospitals, Clinics, Home Healthcare), Distribution (Institution, Pharmacy), Region – Global Forecast to 2030

The global Traditional Wound Care Market , valued at US$7.15 billion in 2024, is forecasted to grow at a robust CAGR of 4.2%, reaching US$7.42 billion in 2025 and an impressive US$9.12 billion by 2030. The increasing prevalence of diabetes, rising cases of traumatic injuries and burn injuries and growing elderly population drives market growth. Additionally, rising awareness about advanced wound care products is expected to impact market growth. Growth potential of emerging countries and cost effectiveness of traditional wound care products also poses an opportunistic factor for market growth.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=217651539

Browse in-depth TOC on “Traditional Wound Care Market“

401 – Tables

50 – Figures

372 – Pages

By Based on application, the traditional wound care market is divided into chronic wounds and acute wounds. Among these, acute wounds hold the largest market share in 2024 due to their increased numbers of road accidents, as well as rise in related injuries. The acute wound care market has 2 segments surgical & traumatic wounds, and burns based for wound type. Both surgical and traumatic wounds need proper assessment, timely intervention, infection prevention, and a tailored wound care plan to support optimal healing and minimize complications. Acute wound care plays an important role in traditional wound management by addressing injuries like cuts, abrasions, and burns. Methods such as cleaning, debridement, and the use of appropriate dressings promote healing and reduce infection risks. Traditional care focuses on creating an optimal environment for tissue repair, with wound management like sterile bandaging and moisture management. Traditional methods remain crucial for handeling acute wounds and fostering successful recovery.

By Based on end user, the traditional wound care market is divided into hospitals & clinics, home healthcare, and ambulatory surgery centers. Among these, home healthcare holds the largest market share in 2024. The driving factor for the traditional wound care market is the aging population, as older population often require wound care due to chronic conditions like diabetes, pressure ulcers, or other injuries. Moreover, home healthcare offers a cheaper alternative at the patience convinence, reducing the need for over budget hospital stays and reducing healthcare expenses for both patients and healthcare providers. Many adults prefer the comfort, privacy, and ease of receiving care in their own homes instead of hospitals & clinics. Wide range of traditional wound care in wound care products, such as dressings and fast aids, make it easier for healthcare professionals to provide effective care remotely. Furthermore, the growing focus on patient care and the desire for personalized treatment plans contribute to the shift toward home healthcare, offering improved outcomes, better patient satisfaction, and a more efficient healthcare delivery model.

By geography, the traditional wound care market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, Middle East & Africa. The Asia Pacific accounts for the largest market share of 37.7% in the traditional wound care market in 2024. This is due to increasing prevalence of diabetese. Additionally, the huge presence of traditional wound care manufacturing companies in the region is increasing the market growth in the region. China is also observing a rise in diabetes which further facilitates the traditional wound care market.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=217651539

Prominent players in the Traditional wound care market include, Solventum (US), Cardinal Health (US), Smith+Nephew (UK), Nitto Denko Corporation (Japan), MCKESSON CORPORATION (US), Beiersdorf (Germany), Owens & Minor, Inc. (US), Essity Aktlebolag (Sweden), PAUL HARTMANN AG (Germany), Kenvue (US), Mölnlycke AB (Sweden), and B. Braun SE (Germany).

Solventum (US):

In April 2024, upon its separation from 3M, Solventum began a new phase as a stand-alone company. Even though it has profited from 3M’s assets and reputation, it is now focusing on creating a distinctive brand identity for itself. To satisfy the demands of customers and patients, Solventum creates, produces, and markets a variety of goods. Company primarily operates in north america through Four business segments: MedSurg, Dental Solutions, Health Information Systems, and Purification & Filtration. To supports growth MedSurg, Dental Solutions, Health Information Systems, and Purification & Filtration. Company is focusing on innovation and strategic expansion.

Cardinal Health (US):

Cardinal Health is a global provider of traditional wound care products, serving Hospitals & Clinics, Home Healthcare, and Ambulatory Surgery Centers. The company offers a wide range of medical products designed to support patient care and improve treatment outcomes. It operates through two main business segments: Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD).With decades of experience, Cardinal Health has made a name for itself in the conventional wound care industry by providing dependable products that meet a range of medical requirements.In addition to the US, Cardinal Health has operations in almost 60 other countries thanks to a wide distribution network and strategic partnerships. Key subsidiaries such as Cardinal Health Ireland 406 Ltd., Cardinal Health Malaysia 211 Sdn. Bhd., Almus Pharmaceuticals Singapore Pte. Ltd., API (Suppliers) Limited (UK), and Cardinal Health P.R. 409 B.V. (Netherlands) enhance the company’s worldwide presence.

Essity Aktlebolag (Sweden):

Essity Aktiebolag provides healthcare and hygiene products to support well-being. Its product range includes personal care items, consumer goods, and hygiene solutions, forming a significant part of its business. The company operates through three main segments: Health & Medical, Consumer Goods, and Professional Hygiene.It provides medical solutions, healthcare items, and incontinence care under the Health & Medical section. Essity offers a range of wound care products under the Leukoplast name.

Essity sold all of its 51.59% ownership in Vinda in March 2024, but it still has brand licensing agreements to conduct business in Asia. Essity supplies its goods to consumers and healthcare providers in 150 countries in Europe, North America, and Latin America. Among its principal subsidiaries are Mölnlycke (Sweden), Vinda (China), Familia (Colombia), and Unicharm (Japan).

For more information, Inquire Now!

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/traditional-wound-care-market-217651539.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Traditional Wound Care Market worth $9.12 billion by 2030 | MarketsandMarkets™

Machine Vision Market worth $23.63 Billion in 2030, at a CAGR of 8.3%

“Machine Vision Market”

The Global Machine Vision Market is expected to grow from USD 15.83 billion in 2025 to USD 23.63 billion by 2030 at a CAGR of 8.3%.

The report “Machine Vision Market by Component (Camera, Frame Grabbers, Optics, LED Lighting, Processors, AI-based Machine Vision Software), Type (PC based, Smart Camera-based), Deployment (General, Robotic Cell), Vision Type (1D, 2D, 3D) – Global Forecast to 2030” The global machine vision market is expected to grow from USD 15.83 billion in 2025 to USD 23.63 billion in 2030, at a CAGR of 8.3%. Governments worldwide support the adoption of various automation technologies for the development of the manufacturing sector. As process industries are a vital part of the manufacturing sector, governments worldwide are focused on bringing automation into the sector.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=234246734

Browse 232 market data Tables and 76 Figures spread through 309 Pages and in-depth TOC on “Machine Vision Market”

View detailed Table of Content here – https://www.marketsandmarkets.com/Market-Reports/industrial-machine-vision-market-234246734.html

The process automation market is especially benefiting from government initiatives. For instance, in 2022, the Government of Singapore partnered with associations such as the Singapore Food Manufacturing Association (SFMA) and the Food Innovation & Resource Centre (FIRC) to deploy the latest automation technologies in the food & beverage industry. Industrial automation helps manufacturing firms mass-produce their products with minimum defects and superior quality, resulting in higher output and better productivity. Machine vision is one of the important systems required for industrial automation. Thus, the increasing government-led initiatives for factory automation worldwide are expected to boost the demand for machine vision and create growth opportunities for the market players.

Smart camera-based machine vision segment to register highest CAGR during forecast year

Smart camera-based machine vision systems consist of an embedded controller with integrated vision software directly connected to one or more cameras, which may differ in image resolution, size, and imaging rates. These systems are generally used for simple tasks such as monitoring and are easy to operate. Different types of smart camera technologies include 2D imaging, 3D sensing, ultrasonic, and infrared. Smart cameras offer a streamlined design that lowers system costs while maintaining functional capacity. When equipped with advanced processors, they can deliver processing performance comparable to that of PC-based systems, enabling them to handle complex machine vision tasks independently without external computing support. Companies manufacturing and distributing smart cameras for machine vision include Basler AG (Germany), Cognex Corporation (US), KEYENCE CORPORATION (US), and Teledyne Technologies Inc. (US).

Consumer product segment expected to register second-highest CAGR during forecast period

Electronics assembly uses machine vision to aid production and test circuitry. Key consumer product manufacturers increasingly deploy machine vision systems to improve quality and productivity. For example, Foxconn uses cameras by Microscan throughout its operations. Typical machine vision applications in this industry include cover glass assembly, touch panel lamination, and screen-printing alignment in display manufacturing. In mobile and wearable device assembly, which requires fast production ramp-up with quick product changeover, machine vision is used for pre-assembly insertion check, post-assembly verification, precision robot guidance, and serial number and bar code reading. Machine vision is also used in alignment, gauging, and machines tending for original equipment manufacturers (OEMs) and machine builders’ display manufacturing and module assembly needs.

Asia Pacific expected to register highest CAGR in machine vision market during forecast period

Asia Pacific is segmented into China, Japan, South Korea, India, Indonesia, Singapore, Australia, and the Rest of Asia Pacific. The strong growth of the economies of China and India and the massive shift to automation and intelligent technologies in different spheres is noteworthy. The Machine Vision Industry in China is growing steadily due to the rising number of industrial automation projects, particularly in the automotive, electronics, and pharmaceutical sectors. India’s machine vision market is booming due to government initiatives such as “Make in India” and the increasing need for quality inspection and process optimization in the manufacturing segment.

Major Players operating in the Machine Vision Companies include Cognex Corporation (US), KEYENCE CORPORATION (Japan), Teledyne Technologies Inc. (US), Basler AG (Germany), and Omron Corporation (Japan).

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Machine Vision Market worth $23.63 Billion in 2030, at a CAGR of 8.3%